Supported by the Else Kroener-Fresenius Foundation, the German Scholars Organization (EKFS/GSO 16), and the BONFOR GEROK Program, Faculty of Medicine, University of Bonn (grant O-137.0028; MW). Carl Zeiss Meditec AG, Jena provided the OCTA device used in this study. The funders had no role in study design, data collection, data analysis, data interpretation, or writing of the manuscript.
Disclosure: J.H. Terheyden, Heidelberg Engineering (F), Optos (F), Carl Zeiss Meditec (F), and CenterVue (F); M.W.M. Wintergerst, D-EYE (F), DigiSight Technologies (F), Heine Optotechnik (F), Heine Optotechnik GmbH (C); C. Pizarro, None; M. Pfau, Heidelberg Engineering (F), Optos (F), Carl Zeiss Meditec (F), and CenterVue (F), Carl Zeiss Meditec AG (C); G.N. Turski, Heidelberg Engineering (F), Optos (F), Carl Zeiss Meditec (F), and CenterVue (F); F.G. Holz, Heidelberg Engineering (F), Optos (F), Carl Zeiss Meditec (F), and CenterVue (F), Acucela (C), Bayer (C), Bioeg (C), Boehringer-Ingelheim (C), Genentech/Roche (C), Heidelberg Engineering (C), Novartis(C), Thea(C), Acucela (F), Allergan (F), Bayer (F), Bioeq (F), Genentech/Roche (F), Merz (F), NightstarX (F), Novartis (F), Allergan (R), Bayer (R), Carl Zeiss MediTec (R), Genentech/Roche (R), Heidelberg Engineering (R), Novartis (R); R.P. Finger, Heidelberg Engineering (F), Optos (F), Carl Zeiss Meditec (F), and CenterVue (F), Bayer (C), Novartis (C), Opthea (C), Novelion (C), Santhera (C), Inositec (C), Alimera (C), Ellex (C), Roche (C), RetinaImplant (C)